Blocking the activation of astrocytes with NLY01, a glucagon-like peptide-1 receptor (GLP1R) agonist, prevented conversion of astrocytes to the proinflammatory A1 phenotype, attenuating dopaminergic neurodegeneration and motor deficits in a mouse model of sporadic PD [50]. This evidence concerns the gene GLP1R and Parkinson disease.